These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6788960)

  • 1. Effect of testosterone enanthate on testis size.
    Palacios A; McClure RD; Campfield A; Swerdloff RS
    J Urol; 1981 Jul; 126(1):46-8. PubMed ID: 6788960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive.
    Brenner PF; Mishell DR; Bernstein GS; Ortiz A
    Contraception; 1977 Jun; 15(6):679-91. PubMed ID: 891194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels.
    Frick J; Bartsch G; Weiske WH
    Contraception; 1977 Jun; 15(6):649-68. PubMed ID: 891192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
    Foegh M; Nicol K; Petersen IB; Schou G
    Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate.
    Frick J; Danner C; Kunit G; Joos H; Köhle R
    Int J Androl; 1982 Jun; 5(3):246-52. PubMed ID: 7118265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters.
    Barfield A; Melo J; Coutinho E; Alvarez-Sanchez F; Faundes A; Brache V; Leon P; Frick J; Bartsch G; Weiske WH; Brenner P; Mishell D; Bernstein G; Ortiz A
    Contraception; 1979 Aug; 20(2):121-7. PubMed ID: 487815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sperm function in Indonesian men treated with testosterone enanthate.
    Arsyad KM
    Int J Androl; 1993 Dec; 16(6):355-61. PubMed ID: 8132379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.
    Bremner WJ; Bagatell CJ; Steiner RA
    J Clin Endocrinol Metab; 1991 Sep; 73(3):465-9. PubMed ID: 1874925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone.
    Pavlou SN; Interlandi JW; Wakefield G; Rivier J; Vale W; Rabin D
    J Androl; 1986; 7(4):228-33. PubMed ID: 3528106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sperm motion parameters after suppression of spermatogenesis with a gonadotropin-releasing hormone antagonist plus testosterone supplementation.
    Bastias MC; Kamijo H; Pavlou SN
    Fertil Steril; 1993 Jun; 59(6):1261-5. PubMed ID: 8495775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.